Mobile

Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma

Mise à jour : Il y a 4 ans
Référence : NCT01912872

Femme et Homme

  • | Pays :
  • Mexico
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess efficacy and safety of omalizumab treatment during 12 months in order to reduce the use of inhaled corticosteroid (ICS) in pediatric and adult patients with severe IgE-mediated asthma inadequately controlled with high doses of corticosteroids.

Critère d'inclusion

  • Severe IgE-mediated Asthma

Liens